Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 2/2014

01-04-2014 | ORIGINAL ARTICLE

AT1 and Aldosterone Receptors Blockade Prevents the Chronic Effect of Nandrolone on the Exercise-Induced Cardioprotection in Perfused rat Heart Subjected to Ischemia and Reperfusion

Authors: Silvio Rodrigues Marques-Neto, Emanuelle Baptista Ferraz, Deivid Carvalho Rodrigues, Brian Njaine, Edson Rondinelli, Antônio Carlos Campos de Carvalho, Jose Hamilton Matheus Nascimento

Published in: Cardiovascular Drugs and Therapy | Issue 2/2014

Login to get access

Abstract

Purpose

Myocardial tolerance to ischaemia/reperfusion (I/R) injury is improved by exercise training, but this cardioprotection is impaired by the chronic use of anabolic androgenic steroids (AAS). The present study evaluated whether blockade of angiotensin II receptor (AT1-R) with losartan and aldosterone receptor (mineralocorticoid receptor, MR) with spironolactone could prevent the deleterious effect of AAS on the exercise-induced cardioprotection.

Methods and Results

Male Wistar rats were exercised and treated with either vehicle, nandrolone decanoate (10 mg/kg/week i.m.) or the same dose of nandrolone plus losartan or spironolactone (20 mg/kg/day orally) for 8 weeks. Langendorff-perfused hearts were subjected to I/R and evaluated for the postischaemic recovery of left ventricle (LV) function and infarct size. mRNA and protein expression of angiotensin II type 1 receptor (AT1-R), mineralocorticoid receptor (MR), and KATP channels were determined by reverse-transcriptase polymerase chain reaction and Western blotting. Postischaemic recovery of LV function was better and infarct size was smaller in the exercised rat hearts than in the sedentary rat hearts. Nandrolone impaired the exercise-induced cardioprotection, but this effect was prevented by losartan (AT1-R antagonist) and spironolactone (MR antagonist) treatments. Myocardial AT1-R and MR expression levels were increased, and the expression of the KATP channel subunits SUR2a and Kir6.1 was decreased and Kir6.2 increased in the nandrolone-treated rat hearts. The nandrolone-induced changes of AT1-R, MR, and KATP subunits expression was normalized by the losartan and spironolactone treatments.

Conclusion

The chronic nandrolone treatment impairs the exercise-induced cardioprotection against ischaemia/reperfusion injury by activating the cardiac renin-angiotensin-aldosterone system and downregulating KATP channel expression.
Literature
1.
Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart Disease and Stroke Statistics–2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146.PubMedCrossRef
2.
World Health Organization. Cardiovascular diseases (CVDs). Fact sheet No. 317, 2011.
3.
4.
Myers J. Cardiology patient pages. Exercise and cardiovascular health. Circulation. 2003;107:e2–5.PubMedCrossRef
5.
Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39:1423–34.PubMedCrossRef
6.
Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116:1094–105.PubMedCrossRef
7.
Leung FP, Yung LM, Laher I, Yao X, Chen ZY, Huang Y. Exercise, vascular wall and cardiovascular diseases: an update (part 1). Sports Med. 2008;38:1009–24.PubMedCrossRef
8.
McElroy CL, Gissen SA, Fishbein MC. Exercise-induced reduction in myocardial infarct size after coronary artery occlusion in the rat. Circulation. 1978;57:958–62.PubMedCrossRef
9.
Bowles DK, Farrar RP, Starnes JW. Exercise training improves cardiac function after ischemia in the isolated, working rat heart. Am J Physiol Heart Circ Physiol. 1992;263:H804–9.
10.
Yamashita N, Baxter GF, Yellon DM. Exercise directly enhances myocardial tolerance to ischemia-reperfusion injury in the rat through a protein kinase C mediated mechanism. Heart. 2001;85:331–6.PubMedCentralPubMedCrossRef
11.
Gielen S, Schuler G, Adams V. Cardiovascular effects of exercise training–molecular mechanisms. Circulation. 2010;122:1221–38.PubMedCrossRef
12.
Frasier CR, Moore RL, Brown DA. Exercise-induced cardiac preconditioning: how exercise protects your achy-breaky heart. J Appl Physiol. 2011;111:905–15.PubMedCrossRef
13.
Brown DA, Chicco AJ, Jew KN, Johnson MS, Lynch JM, Watson PA, et al. Cardioprotection afforded by chronic exercise is mediated by sarcolemmal, and not the mitochondrial, isoform of the KATP channel in the rat. J Physiol. 2005;569:913–24.PubMedCentralPubMedCrossRef
14.
Brown DA, Lynch JM, Armstrong CJ, Caruso NM, Ehlers LB, Johnson MS, et al. Susceptibility of the heart to ischaemia-reperfusion injury and exercise-induced cardioprotection are sex-dependent in the rat. J Physiol. 2005;564:619–30.PubMedCentralPubMedCrossRef
15.
Chicco AJ, Johnson MS, Armstrong CJ, Lynch JM, Gardner RT, Fasen GS, et al. Sex-specific and exercise-acquired cardioprotection is abolished by sarcolemmal KATP channel blockade in the rat heart. Am J Physiol Heart Circ Physiol. 2007;292:H2432–7.PubMedCrossRef
16.
Quindry JC, Schreiber L, Hosick P, Wrieden J, Irwin JM, Hoyt E. Mitochondrial KATP channel inhibition blunts arrhythmia protection in ischemic exercised hearts. Am J Physiol Heart Circ Physiol. 2010;299:H175–83.PubMedCentralPubMedCrossRef
17.
Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–54.PubMedCrossRef
18.
Sjӧqvist F, Garle M, Rane A. Use of doping agents, particularly anabolic steroids, in sports and society. Lancet. 2008;371:1872–82.CrossRef
19.
Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41:1–15.PubMedCrossRef
20.
Di Paolo M, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M, et al. Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol. 2007;114:114–7.PubMedCrossRef
21.
Fineschi V, Baroldi G, Monciotti F, Reattelli LP, Turillazzi E. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med. 2001;125:253–5.PubMed
22.
23.
Du Toit EF, Rossouw E, Van Rooyen J, Lochner A. Proposed mechanisms for the anabolic steroid-induced increase in myocardial susceptibility to ischemia/reperfusion injury. Cardiovasc J South Afr. 2005;16:21–8.
24.
Chaves EA, Pereira-Junior PP, Fortunato RS, Masuda MO, Carvalho ACC, Carvalho DP, et al. Nandrolone decanoate impairs exercise-induced cardioprotection: role of antioxidant enzymes. J Steroid Biochem Mol Biol. 2006;99:223–30.PubMedCrossRef
25.
Rocha FL, Carmo EC, Roque FR, Hashimoto NY, Rossoni LV, Frimm C, et al. Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats. Am J Physiol Heart Circ Physiol. 2007;293:H3575–83.PubMedCrossRef
26.
Do Carmo EC, Fernandes T, Koike D, Da Silva Jr ND, Mattos KC, Rosa KT, et al. Anabolic steroid associated to physical training induces deleterious cardiac effects. Med Sci Sports Exerc. 2011;43:1836–48.PubMedCrossRef
27.
Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98:256–61.PubMedCrossRef
28.
Iwai N, Shimoike H, Kinoshita M. Cardiac rennin-angiotensin system in the hypertrophied heart. Circulation. 1995;92:2690–6.PubMedCrossRef
29.
Barauna VG, Magalhaes FC, Krieger JE, Oliveira EM. AT1 receptor participates in the cardiac hypertrophy induced by resistance training in rats. Am J Physiol Regul Integr Comp Physiol. 2008;295:R381–7.PubMedCrossRef
30.
Zhang AD, Cat AND, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension. 2008;52:1060–7.PubMedCrossRef
31.
Kalra D, Sivasubramanian N, Mann DL. Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C–dependent pathway. Circulation. 2002;105:2198–205.PubMedCrossRef
32.
Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. 1998;98:794–9.
33.
Tavares NI, Philip-Couderc P, Baertschi AJ, Lerch R, Montessuit C. Angiotensin II and tumour necrosis factor α as mediators of ATP-dependent potassium channel remodeling in post-infarction heart failure. Cardiovasc Res. 2009;83:726–36.CrossRef
34.
Serejo FC, Rodrigues-Junior LF, Tavares KCS, Campos de Carvalho AC, Nascimento JHM. Cardioprotective properties of humoral factors released from rat hearts subject to ischemic preconditioning. J Cardiovasc Pharmacol. 2007;49:214–20.PubMedCrossRef
35.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101–8.PubMedCrossRef
36.
Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 1999;33:981–6.PubMedCrossRef
37.
Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation. 2002;105:677–9.PubMedCrossRef
38.
Silvestre JS, Heymes C, Oubénaïssa A, Robert V, Aupetit-Faisant B, Carayon A, et al. Activation of cardiac aldosterone production in rat myocardial infarction. Circulation. 1999;99:2694–701.PubMedCrossRef
39.
Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992;20:67–73.PubMedCrossRef
40.
Mill JG, Milanez MC, Rezende MM, Gomes MGS, Leite CM. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol. 2003;30:739–44.PubMedCrossRef
41.
Chai W, Garrelds IM, Arulmani U, Schoemaker RG, Lamers JMJ, Danser AHJ. Genomic and nongenomic effects of aldosterone in the rat: why is spironolactone cardioprotective. Br J Pharmacol. 2005;145:664–71.PubMedCentralPubMedCrossRef
42.
Sato M, Engelman RM, Otani H, Maulik N, Rousou JA, Flack III JE, et al. Myocardial protection by preconditioning of heart with losartan, na angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation. 2000;102(Supl 3):346–51.
43.
Flynn JD, Akers WS. Effects of the angiotensin II subtype 1 receptor antagonist losartan on functional recovery of isolated rat hearts undergoing global myocardial ischemia-reperfusion. Pharmacotherapy. 2003;23:1401–10.PubMedCrossRef
44.
Tsounapi P, Saito M, Dimitriadis F, Kitatani K, Kinoshita Y, Shomori K, et al. The role of KATP channels on ischemia-reperfusion injury in the rat testis. Life Sci. 2012;90:649–56.PubMedCrossRef
45.
Seharaseyon J, Sasaki N, Ohler A, Sato T, Fraser H, Johns DC, et al. Evidence against functional heteromultimerization of the KATP channel subunits Kir6.1 and Kir6.2. 275. J Biol Chem. 2000;23:17561–5.CrossRef
46.
Flagg TP, Kurata HT, Masia R, Caputa G, Magnuson MA, Lefer DJ, et al. Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1. Circ Res. 2008;103:1458–65.PubMedCentralPubMedCrossRef
47.
Morrissey A, Rosner E, Lanning J, Parachuru L, Chowdhury PD, Han S, et al. Immunolocalization of KATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. BMC Physiol. 2005;5:1.PubMedCentralPubMedCrossRef
48.
Seharaseyon J, Ohler A, Sasaki N, Fraser H, Sato T, Johns DC, et al. Molecular composition of mitochondrial ATP-sensitive potassium channels probed by viral Kir gene transfer. J Mol Cell Cardiol. 2000;32:1923–30.PubMedCrossRef
49.
Cuong DV, Kim N, Joo H, Youm JB, Chung J-Y, Lee Y, et al. Subunit composition of ATP-sensitive potassium channels in mitochondria of rat hearts. Mitochondrion. 2005;5:121–33.PubMedCrossRef
50.
51.
Kubo M, Quayle JM, Standen NB. Angiotensin II inhibition of ATP-sensitive K+ currents in rat arterial smooth muscle cells through protein kinase C. J Physiol. 1997;503:480–96.CrossRef
52.
Sampson LJ, Davies LM, Barrett-Jolley R, Standen NB, Dart C. Angiotensin II-activated protein kinase C targets caveolae to inhibit aortic ATPsensitive potassium channels. Cardiovasc Res. 2007;76:61–70.PubMedCrossRef
Metadata
Title
AT1 and Aldosterone Receptors Blockade Prevents the Chronic Effect of Nandrolone on the Exercise-Induced Cardioprotection in Perfused rat Heart Subjected to Ischemia and Reperfusion
Authors
Silvio Rodrigues Marques-Neto
Emanuelle Baptista Ferraz
Deivid Carvalho Rodrigues
Brian Njaine
Edson Rondinelli
Antônio Carlos Campos de Carvalho
Jose Hamilton Matheus Nascimento
Publication date
01-04-2014
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 2/2014
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-013-6503-8

Other articles of this Issue 2/2014

Cardiovascular Drugs and Therapy 2/2014 Go to the issue

REVIEW ARTICLE

AMP Deaminase 1 Gene Polymorphism and Heart Disease—A Genetic Association That Highlights New Treatment

REVIEW ARTICLE

Reduced Oxidative Stress in STEMI Patients Treated by Primary Percutaneous Coronary Intervention and with Antioxidant Therapy: A Systematic Review

ORIGINAL ARTICLE

METformin in DIastolic Dysfunction of MEtabolic Syndrome (MET-DIME) Trial: Rationale and Study Design

ORIGINAL ARTICLE

Protective Effects of Aliskiren on Atrial Ionic Remodeling in a Canine Model of Rapid Atrial Pacing

ORIGINAL ARTICLE

Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats

LETTER TO THE EDITOR

Nitric Oxide and Takotsubo Syndrome: an “Angle” in Need of Exploration and Exploitation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits